| 2016-12-01 08:05:08|
AGRX 08:05 12/01 12/01/16
Agile Therapeutics receives about $3M in non-dilutive funding from NJEDA
Agile Therapeutics announced that it has received net proceeds of approximately $3M in non-dilutive financing through the State of New Jersey's Technology Business Tax Certificate Transfer Program. The Program enables biotechnology companies to raise funds to finance their growth and operations and is administered by the New Jersey Economic Development Authority, or NJEDA, and the New Jersey Department of the Treasury's Division of Taxation.